Genesis and regulation of C-terminal cyclic imides from protein damage

W Wenqing Xu Z Zhenguang Zhao (Institute of Chemistry) M Matthew Su (Department of Chemistry and Chemical Biology, Harvard University) A Atul D. Jain (Novo Nordisk R&D US,) H Hannah C. Lloyd (Department of Chemistry and Chemical Biology, Harvard University) E Ethan Yang Feng (Department of Chemistry and Chemical Biology, Harvard University) N Nick Cox (Novo Nordisk R&D US,) C Christina M. Woo

Abstract

C-Terminal cyclic imides are posttranslational modifications that can arise from spontaneous intramolecular cleavage of asparagine or glutamine residues resulting in a form of irreversible protein damage. These protein damage events are recognized and removed by the E3 ligase substrate adapter cereblon (CRBN), indicating that these aging-related modifications may require cellular quality control mechanisms to prevent deleterious effects. However, the factors that determine protein or peptide susceptibility to C-terminal cyclic imide formation or their effect on protein stability have not been explored in detail. Here, we characterize the primary and secondary structures of peptides and proteins that promote intrinsic formation of C-terminal cyclic imides in comparison to deamidation, a related form of protein damage. Extrinsic effects from solution properties and stressors on the cellular proteome additionally promote C-terminal cyclic imide formation on proteins like glutathione synthetase that are susceptible to aggregation if the protein damage products are not removed by CRBN. This systematic investigation provides insight into the regions of the proteome that are prone to these unexpectedly frequent modifications, the effects of this form of protein damage on protein stability, and the biological role of CRBN.

Article Details

Volume / Issue Vol. 122, Issue 1
Published January 07, 2025
ISSN 0027-8424
Publisher National Academy of Sciences

Authors (8)

W

Wenqing Xu

Z

Zhenguang Zhao

Institute of Chemistry

M

Matthew Su

Department of Chemistry and Chemical Biology, Harvard University

A

Atul D. Jain

Novo Nordisk R&D US,

H

Hannah C. Lloyd

Department of Chemistry and Chemical Biology, Harvard University

E

Ethan Yang Feng

Department of Chemistry and Chemical Biology, Harvard University

N

Nick Cox

Novo Nordisk R&D US,

C

Christina M. Woo